These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 8797768)

  • 21. Preferential killing of breast tumor initiating cells by N,N-diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine/tesmilifene.
    Deng T; Liu JC; Pritchard KI; Eisen A; Zacksenhaus E
    Clin Cancer Res; 2009 Jan; 15(1):119-30. PubMed ID: 19118039
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Double high-dose chemotherapy with stem cell rescue (HD-SCR) in patients with breast cancer - effect of sequence.
    Frei E; Ara G; Teicher B; Bunnell C; Richardson P; Wheeler C; Tew K; Elias A
    Cancer Chemother Pharmacol; 2000; 45(3):239-46. PubMed ID: 10663642
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Influence of schedule on alkylating agent cytotoxicity in vitro and in vivo.
    Teicher BA; Holden SA; Eder JP; Brann TW; Jones SM; Frei E
    Cancer Res; 1989 Nov; 49(21):5994-8. PubMed ID: 2790813
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combination of N,N',N"-triethylenethiophosphoramide and cyclophosphamide in vitro and in vivo.
    Teicher BA; Holden SA; Cucchi CA; Cathcart KN; Korbut TT; Flatow JL; Frei E
    Cancer Res; 1988 Jan; 48(1):94-100. PubMed ID: 3121169
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modulation of alkylating agents by etanidazole and Fluosol-DA/carbogen in the FSaIIC fibrosarcoma and EMT6 mammary carcinoma.
    Teicher BA; Herman TS; Tanaka J; Eder JP; Holden SA; Bubley G; Coleman CN; Frei E
    Cancer Res; 1991 Feb; 51(4):1086-91. PubMed ID: 1825474
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE), is highly active against primary uterine serous papillary carcinoma cell lines in vitro.
    Bellone S; Black J; English DP; Schwab CL; Lopez S; Cocco E; Bonazzoli E; Predolini F; Ferrari F; Ratner E; Silasi DA; Azodi M; Schwartz PE; Santin AD
    Am J Obstet Gynecol; 2016 Jan; 214(1):99.e1-8. PubMed ID: 26272866
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preclinical studies relating to the use of thiotepa in the high-dose setting alone and in combination.
    Teicher BA; Holden SA; Eder JP; Herman TS; Antman KH; Frei E
    Semin Oncol; 1990 Feb; 17(1 Suppl 3):18-32. PubMed ID: 2106164
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Host distribution and response to antitumor alkylating agents of EMT-6 tumor cells from subcutaneous tumor implants.
    Holden SA; Emi Y; Kakeji Y; Northey D; Teicher BA
    Cancer Chemother Pharmacol; 1997; 40(1):87-93. PubMed ID: 9137536
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cell-cycle disruptions and apoptosis induced by the cyclophosphamide derivative mafosfamide.
    Davidoff AN; Mendelow BV
    Exp Hematol; 1993 Jul; 21(7):922-7. PubMed ID: 8319782
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Zoledronic acid is unable to induce apoptosis, but slows tumor growth and prolongs survival for non-small-cell lung cancers.
    Li YY; Chang JW; Chou WC; Liaw CC; Wang HM; Huang JS; Wang CH; Yeh KY
    Lung Cancer; 2008 Feb; 59(2):180-91. PubMed ID: 17900752
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adhesion-dependent multicellular drug resistance.
    Green SK; Frankel A; Kerbel RS
    Anticancer Drug Des; 1999 Apr; 14(2):153-68. PubMed ID: 10405642
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro test-system for chemo- and thermosensitivity: an analysis of survival fractions and cell-cycle distributions in human Ewing's sarcomas as a modelfor tumors in pediatric oncology.
    Debes A; Rommel F; Breise M; Willers R; Göbel U; Wessalowski R
    Klin Padiatr; 2002; 214(4):223-9. PubMed ID: 12165906
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro cell cycle arrest, in vivo action on solid metastasizing tumors, and host toxicity of the antimetastatic drug NAMI-A and cisplatin.
    Bergamo A; Gagliardi R; Scarcia V; Furlani A; Alessio E; Mestroni G; Sava G
    J Pharmacol Exp Ther; 1999 Apr; 289(1):559-64. PubMed ID: 10087050
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of cyclin D1 overexpression on drug sensitivity in a human fibrosarcoma cell line.
    Hochhauser D; Schnieders B; Ercikan-Abali E; Gorlick R; Muise-Helmericks R; Li WW; Fan J; Banerjee D; Bertino JR
    J Natl Cancer Inst; 1996 Sep; 88(18):1269-75. PubMed ID: 8797766
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CAI: effects on cytotoxic therapies in vitro and in vivo.
    Teicher BA; Holden SA; Chen YN; Ara G; Korbut TT; Northey D
    Cancer Chemother Pharmacol; 1994; 34(6):515-21. PubMed ID: 7923563
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of RSR13 and oxygen on the cytotoxicity of cisplatin and carboplatin to EMT6 mouse mammary tumor cells in vitro and in vivo.
    Donnelly ET; Kelley M; Rockwell S
    Cancer Chemother Pharmacol; 2004 Jan; 53(1):43-50. PubMed ID: 14574460
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of hyaluronidase on doxorubicin penetration into squamous carcinoma multicellular tumor spheroids and its cell lethality.
    Kohno N; Ohnuma T; Truog P
    J Cancer Res Clin Oncol; 1994; 120(5):293-7. PubMed ID: 8126058
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth Inhibition, G2-M arrest, and apoptosis.
    Tyagi AK; Singh RP; Agarwal C; Chan DC; Agarwal R
    Clin Cancer Res; 2002 Nov; 8(11):3512-9. PubMed ID: 12429642
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differential regulation of cyclin-dependent kinase inhibitors in monolayer and spheroid cultures of tumorigenic and nontumorigenic fibroblasts.
    LaRue KE; Bradbury EM; Freyer JP
    Cancer Res; 1998 Mar; 58(6):1305-14. PubMed ID: 9515820
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular characterization of the in vivo alkylating agent resistant murine EMT-6 mammary carcinoma tumors.
    Chatterjee D; Liu CJ; Northey D; Teicher BA
    Cancer Chemother Pharmacol; 1995; 35(5):423-31. PubMed ID: 7850925
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.